The syntheses of combretastatin A-4 from gallic acid and of three combretastatin-based hybrids are described. Starting from commercial gallic acid, the phosphonium salt (3,4,5-trimethoxybenzylphosphonium bromide) is synthesized and coupled, through a Wittig reaction, with several aldehydes, including methoxymethyl-protected isovanillin, the aldehyde γ-bicyclohomofarnesal having a labdane skeleton, 3-(3-pyridyl) propanal, and furfural. The biological properties of the cis-coupled compounds as cytotoxic, antiviral and antifungal agents are also reported. In addition, pyrogallol, gallic and 3,4,5trimethoxybenzoic acids have been studied biologically.
Combretastatin A-4 (CA-4, 1) ( Figure 1) is isolated from the African willow tree Combretum caffrum and has been known for over 20 years ago [1] . It is a strong tubulin depolymerizing agent and, therefore, inhibits tumor growth and has antivascular effects [2] . Its prodrug (disodium salt, water-soluble phosphate derivative, CA-4P, 2) has entered clinical trials for both solid and liquid tumors [3] . Similarly, a close derivative of CA-4 (AVE-8062, 3) is also undergoing clinical trials [4] . Both compounds have demonstrated a sufficient safety profile in phase I trials, suggesting that this may be a viable therapeutic strategy. 1, Combretastatin A-4 (CA-4) R=OH 2, Combretastatin A-4P (CA-4P) R=OPO 3 Na 2 3, AVE-8062 R=NH-Serine Despite its low molecular weight and simple molecular structure, CA-4 is one of the most powerful inhibitors of tubulin polymerization known to date. The structure can be divided into three separate components, the two rings (usually termed A and B) and the olefinic bridge. The structure-activity relationship (SAR) of CA-4 has been investigated thoroughly by a number of groups, being reasonably well-understood, and medicinal chemistry has been largely explored on its carbon framework [5] . In brief, it is thought that the cis-configuration of the olefinic bridge, the presence of the 3,4,5-trimethoxy group on ring A, and the paramethoxy group on ring B are fundamental for antitubulin activity. However, active compounds not obeying this general rule have been described [6] . Thus, modifications of the CA-4 structure have led to a great number of novel CA-4 derivatives as potent tubulin inhibitors. Among these derivatives, a number of combretastatinbased hybrids have been the objective of several research groups, for example, the synthesis and biological properties of combretastatin-based hybrids with colchicines [7] , lamellarins [8], chromone [9] , and chalcone [10] . On the basis of this motivation, in this study, and based on our prior experience with other bioactive molecules, we planned to select the 3,4,5-trimethoxybenzene and the cis-olefinic bridge moieties present in CA-4 as the core structure. Therefore, in this study we have combined important pharmacophore structures of combretastatins with bioactive carbon frameworks to design several hybrids, which have been studied as cytotoxic, antiviral and antifungal agents ( Figure 2 ). In addition, pyrogallol (12) , gallic acid (13) and 3,4,5-trimethoxybenzoic acid (14) (trimethylgallic acid) have also been studied biologically.
As parent carbon frameworks to combine with the 3,4,5trimethoxybenzene moiety through a cis-olefinic bridge, we have chosen two terpenoid skeletons that have shown a high bioactive profile, abietic acid (4) [11] , and the natural dialdehyde belonging to the labdane class of terpenoids, labdadienedial (5) ( Figure 2 ) [12] . Also, we wanted to introduce a 3-alkylpyridine moiety, which is present in natural bioactive pyridine alkaloids 6, as antineoplastic theonelladin A and anti-microfouling untenine A [13] . Finally, we wanted to introduce a furan ring, through furfural 7, to see the influence of this on bioactivity.
Our retrosynthesis towards CA-4 and the combretastatin-based hybrids focused on the Wittig reaction (Scheme 1) between the known phosphonium salt, 3,4,5-trimethoxybenzylphosphonium bromide (18) [14] , which was synthesized from gallic acid (13), and several readily available aldehydes, such as methoxymethylprotected isovainillin 20 (Scheme 2) [15] , and the aldehyde abietinal (23) , prepared from abietic acid [11] , the aldehyde bicyclohomofarnesal (26) prepared from (+)-sclareolide [16], 3-(3pyridyl)propanal (28) prepared by Dess-Martin oxidation of 3-(3pyridyl) propanol (27) [13b], and commercial furfural 7. Aldehydes 23 and 26 are known intermediates in the synthesis of different terpenoid systems and both can be prepared in three steps starting from commercial (-)-abietic acid and commercial (+)-sclareolide, respectively [11, 12] . The key Wittig reaction with ylide derived from phosphonium salt 18 has precedent in the literature, and has already been reported with different protecting groups in the aldehyde counterpart in the synthesis of combretastatin A-4 [17] . Thus, the introduction of the 3,4,5-trimethoxybenzene and cis-olefin moieties to obtain CA-4 was easy, but, the introduction of these moieties into other aldehyde systems represented a challenge for us.
The synthesis began with the alkylation and esterification of gallic acid (13) using dimethyl sulfate in basic media to afford trimethoxyester (methyl 3,4,5-trimethoxybenzoate) 15 (80%) (Scheme 1). The control of the esterification step led to the isolation of trimethylgallic acid (92%, 14) as intermediate. Then, reduction of the ester in 15 with LiAlH 4 in THF gave the corresponding benzyl alcohol 16 in 88% yield, which was converted to its corresponding bromide 17 (80%) by reaction with CBr 4 /PPh 3 in DCM. Finally, treatment of bromide 17 with triphenylphosphine in refluxing toluene led to the key phosphonium salt 18 in quantitative yield (Scheme 1) [14] .
Reagents
Next, we carried out the synthesis of the necessary aldehydes for the Wittig reaction with the ylide derived from phosphonium salt 18 (Scheme 2). First, we protected commercial isovanillin (19) as its corresponding methoxymethyl ether using MOMCl/K 2 CO 3 to afford MOM-ether 20 in 76% yield [15] . Abietic acid (4) was esterified by treatment with lithium hydroxide and dimethyl sulfate to give ester 21 in quantitative yield. Reduction of ester 21 with LiAlH 4 in dry tetrahydrofuran under reflux gave alcohol (abietinol) 22 in quantitative yield. Oxidation of 22 was carried out by treatment with PCC on alumina [18] . This oxidation afforded the desired aldehyde (abietinal) 23 in 40% yield [11] . Next, we synthesized the aldehyde -bicyclohomofarnesal (26) from commercially available (+)-sclareolide. Thus, (+)-sclareolide was reacted with the dimethylaluminum amide derived from N-methoxy-N-methylamine yielding the desired Weinreb´s amide 24 in 85% yield (Scheme 2). The tertiary alcohol of amide 24 was dehydrated in the presence of SOCl 2 /pyridine at -78ºC to give essentially the exo-isomer 25 in 90% yield. Finally, compound 25 was treated with DIBAL-H at -78ºC to give the desired aldehyde 26 in 92% yield [12] . 3-Pyridinepropanol 27 was oxidized with Dess-Martin periodinane to give the desired 3-pyridinepropanal 28 in 96% yield. Commercial furfural (7) was used as received without purification.
With the aldehydes 7, 20, 23, 26, and 28 in hand, our next objective was to accomplish the key Wittig reaction to introduce the 3,4,5trimethoxybenzene and cis-olefinic bridge moieties. The necessary ylide derived from phosphonium salt 18 was generated with butyllithium in THF at -30ºC prior to the addition of the different aldehydes at this temperature and then allowing the mixture to warm to room temperature slowly. All reactions worked giving the corresponding cis-stilbenes 9-11 and MOM-protected CA-4, after careful silica gel column chromatography, with good yields (65-90%) and Z:E (ratio ca. 2:1 to 4:1) selectivity, except for the reaction with abietinal 23 to afford 8 that failed, probably due to steric hindrance present in the reacting aldehyde group. Combretastatin A-4 (1) was obtained after deprotection of the MOM-protected molecule with refluxing acetic acid in water (8:2) (90%). Compounds 1 and 11 are previously known [1, 19] , while 9 and 10 are new.
The combretastatin-based hybrids 9-11, combretastatin A-4 (1) itself, and compounds 12-14 were tested in vitro for potential antitumor and cytotoxic activities by determining the concentration of the compound that induces 50% growth inhibition (IC 50 ) on the HeLa tumor cell line and non-tumor Vero cell line, respectively ( Table 1 ). The antitumor activity on HeLa cells, and cytotoxic activity on Vero cells have been carried out using the tetrazoliumdye (MTT) assay in vitro on cell growth according to the protocol reported by us [20] , which was used with a few modifications. Vincristine was used as positive control. All these compounds produced a dose-dependent inhibition of the growth of cell lines, with R 2 (coefficient of linear regression) > 0.8. The derivatives 1, 11 and 12 showed in vitro potential antitumor activity. The combretastatin-hybrid 11 with a furan ring showed the highest potential antitumor activity on the HeLa tumor line with an IC 50 value of 3.0  0.5 g/mL. However, the compound with the highest selectivity index (SI) was pyrogallol (12) . The susceptibility of tumor cell lines to pyrogallol has also been exhibited for A549 lung cancer cells and its non-cytotoxicity to MRC-5 normal lung fibroblasts [21] . Selectivity refers to the ability of a compound to recognize its target without interacting with other targets. Recently, an SI value of 14.3 on cell lines is indicative of potential antitumor activity for biopharmaceutical use [22] . Therefore, the combretastatin-hybrid 11 with a SI value of 9.63 could be a possible antitumor agent.
All compounds 1, 9-14 were tested for anti-Candida, anti-Aspergillus, anti-Fusarium and anti-dermatophyte activity. The antifungal activity was evaluated following the standard method proposed by the Antifungal Susceptibility Testing Subcommittee of the European Committee on Antibiotic Susceptibility Testing (AFST EUCAST) [23] for fermentative yeasts and the Clinical and were used as positive controls with Candida spp., Aspergillus spp. and dermatophytes species, respectively, where the MIC values for the three reference drugs were within the established values for the standard protocols (Table 2 ). The compounds did not show activity against Candida parapsilopsis, C. krusei, C. tropicalis, C. albicans, Aspergillus flavus and Fusarium oxysporum at concentrations lower than 100.0 µg/mL, except the pyrogallol compound 12 that showed MIC values of 6.25 ± 0 µg/mL, 25.0 ± 0 µg/mL, 79.4 ± 25.8 µg/mL, 100 ± 0 µg/mL, 396.9 ± 129.1 µg/mL and 79.4 ± 28.9 µg/mL, respectively (data not shown). Moreover, the combretastatin-based hybrid 9 and compound 14 did not show activity against any fungi evaluated ( Table 2) .
Studies of antifungal activity against Candida, Aspergillus, Fusarium and dermatophyte species of pyrogallol have not been reported so far. Furthermore, in previous studies, Pettit et al. [25] did not find anti-Candida activity for combretastatin A-4 (1), however, a combretastatin-hybrid with a nitroethylene moiety, the 3,4,5trimethoxy-β-nitrostyrene, showed activity against C. albicans ATCC 90028 (MIC = 32.0 µg/mL). In this study, pyrogallol (12) also showed MIC values of 396.8 ± 129.1 µg/mL against A. fumigates, 31.5 ± 14.4 µg/mL against A. terreus and 25 ± 0 µg/mL against T. rubrum and T. mentagrophytes. In addition, gallic acid (13) had activity against T. rubrum and T. mentagrophytes (MIC = 50.0 ± 0 µg/mL and 39.7± 12.9 µg/mL, respectively). Moreover, the combretastatin-based hybrid 11 and combretastatin A-4 (1) showed MIC values much lower than those of compounds 
a Geometric means of minimal inhibitory concentration of tested compounds in µg/mL. 12 and 13 against A. fumigatus and the dermatophytes Trichophyton rubrum and T. mentagrophytes, the hybrid 11 showing the highest activity in all cases (MIC = 19.8 ± 6.5 µg/mL, 15.7 ± 6.7 µg/mL and 15.7 ± 6. 4 µg/mL, respectively). Furthermore, only the combrestastatin-hybrid 11 showed activity against Aspergillus terreus with an MIC value of 63.0 ± 25.8 µg/mL. It is important to note that Aspergillus fumigatus is the most important mold causing fungemia and is known to have high resistance to many antimycotic agents. On the other hand, dermatophytes are the most common etiological agents of the superficial fungal infection known as dermatophytosis, which affects skin, hair and nails. To the best of our knowledge, this is the first report of antifungal activity on Aspergillus spp. and dermatophyte species of combretastatin A-4 (1), combrestastatin-based hybrids, and gallic acid derivatives.
The antiviral activity of compounds 1, 9-14 against Herpes simplex virus type 1 (HHV-1), obtained from the Center for Disease Control (Atlanta, GA) and HHV-2 (ATCC VR-734, strain G) was carried out on Vero cells using an end-point titration technique, according to the protocol reported by us [26] , which was used with a few modifications [27] . Combretastatin A-4 and hybrid 9 showed activities against HHV, and reduced HHV-2 replication with concentrations below 25.0 and 3.1 µg/mL, respectively (Table 3) . Gallic acid (13) showed the highest antiviral activity for HHV-1 and HHV-2.
According to Vlietinck et al. [28] , only compounds with a reduction factor (Rf) of the viral titer over 1 x 10 3 (Rf: ratio of the virus titer in the absence over virus titer in the presence of the tested compound) show relevant antiviral activity. Gallic acid (13) was found to be slightly active against HHV-1 and HHV-2 over infected confluent monolayers of Vero cells with an Rf value of 1x10 1 and 1x10 2 at a concentration of 6.25 µg/mL. Kratz et al. [29] have reported the activity of gallic acid and pentyl gallate against HHV-1 and HHV-2 1054 Natural Product Communications Vol. 7 (8) 2012
González et al. [29, 30] . This is the first time that anti-herpetic activity of combretastatin A-4 (1) and combrestastatin-based hybrids is described.
Experimental
Chemistry: Optical rotations were determined using a 5 cm pathlength cell, using dichloromethane as solvent (concentration expressed in g/100 mL).
[α] D -Values are given in 10 -1 deg cm 2 /g. NMR spectra were recorded on a 300 MHz spectrometer with tetramethylsilane as an internal standard. All spectra were recorded in CDCl 3 , unless otherwise described. with dermatophytes were used as positive controls at a range of 0.031-16.0 µg/mL. The inoculum sizes for microdilution plates were 0.5 -2.5 x 10 5 and 0.2-2.5 x 10 5 CFU/mL for yeast and filamentous fungi, respectively. For the AFST-EUCAST method, the Minimal Inhibitory Concentrations (MICs) were determined after 24 h at 35°C of incubation by spectrophotometric reading at 405 nm and is defined as the lowest concentration that resulted in a 90% reduction of growth. For the CLSI M38-A method, the MICs were determined after 48 h of incubation at 35 0 C for Aspergillus spp. and at 28°C for F. oxysporum. The activity against the dermatophytes was determined after 6 days of incubation at 28°C. The MICs were defined as the lowest dilution that resulted in 80% inhibition of visible growth. MIC results were expressed as range and geometric mean (GM) of duplicates of each compound tested 3 times against each of the fungal species in different assays.
Antiviral activity:
Herpes simplex virus types 1 and 2 were obtained from the Center for Disease Control (Atlanta, GA). Virus stocks (HHV-1 and HHV-2) were prepared from infected Vero cell cultures using an end-point titration technique. Two-fold dilutions of the compounds and viral suspension (one infection dose, 1 D.I.) were mixed and incubated for 0.5 h at 21°C before they were added onto confluent monolayer cells and incubated again at 37°C in a humidified 5% CO 2 atmosphere for 36 h. Acyclovir and heparin sodium salt were used as positive controls.
